Identifying Secondary Progressive Multiple Sclerosis

Key opinion leaders review disease-modifying medications available for patients with multiple sclerosis in order to guide best practices in management.

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Moving the MS Treatment Paradigm Forward
November 01, 2019 – 
Concluding their discussion, experts share closing thoughts on the future management of multiple sclerosis (MS).
Multiple Sclerosis: Balancing Cost and Access to Therapy
October 25, 2019 – 
Key opinion leaders compare the value of disease modifying therapy against its cost in the evolving treatment paradigm of multiple sclerosis.
Cost of Disease-Modifying Therapy in Multiple Sclerosis
October 25, 2019 – 
The panel takes time to define the cost of disease-modifying therapy in multiple sclerosis.
Optimizing the Use of Disease Modifying Therapy in Multiple Sclerosis
October 18, 2019 – 
Following perspective on cladribine in multiple sclerosis, panelists provide insight on selection and use amid disease-modifying therapy.
Siponimod's Role in Managing Multiple Sclerosis
October 18, 2019 – 
Experts home in on the benefit of siponimod, a sphingosine 1-phosphate receptor modulator, in managing multiple sclerosis.
Ocrelizumab Use in Treating Multiple Sclerosis
October 11, 2019 – 
A panel of experts considers the role of ocrelizumab, an anti-CD20 monoclonal antibody, in treating multiple sclerosis.
Approaching the Management of Multiple Sclerosis
October 11, 2019 – 
Focusing on the management of multiple sclerosis, the panel outlines available nonpharmacologic and pharmacologic strategies.
How Are Outcomes of Progressive MS Measured?
October 03, 2019 – 
Key opinion leaders briefly discuss outcome-measurement strategies as they relate to progressive multiple sclerosis (MS).
Role of a Specialist Versus PCP in Multiple Sclerosis
October 03, 2019 – 
Perspectives on the respective roles of a primary care physician (PCP) versus a specialist when identifying and managing multiple sclerosis.
Discrepancy in Defining Secondary-Progressive Multiple Sclerosis
September 26, 2019 – 
The panel emphasizes challenges faced when attempting to identify secondary-progressive multiple sclerosis.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.